Nutriband Inc. (NTRB)
NASDAQ: NTRB
· Real-Time Price · USD
6.30
-0.58 (-8.43%)
At close: May 01, 2025, 3:57 PM
6.61
4.92%
After-hours: May 01, 2025, 05:31 PM EDT
-8.43% (1D)
| Bid | 6.3 |
| Market Cap | 70.27M |
| Revenue (ttm) | 2.02M |
| Net Income (ttm) | -6.85M |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | -6.36 |
| Forward PE | -12.24 |
| Analyst | Buy |
| Ask | 7.11 |
| Volume | 146,946 |
| Avg. Volume (20D) | 74,083 |
| Open | 7.27 |
| Previous Close | 6.88 |
| Day's Range | 6.30 - 7.35 |
| 52-Week Range | 3.30 - 11.78 |
| Beta | 0.95 |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Website https://nutriband.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 106.35% from the latest price.
Stock Forecasts2 months ago
+17.09%
Nutriband shares are trading higher after the comp...
Unlock content with
Pro Subscription
3 months ago
+40.88%
Nutriband shares are trading higher after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $13 price target.